Fungal infections should be part of the core outcome set for COVID-19

Lancet Infect Dis. 2021 Jun;21(6):e145. doi: 10.1016/S1473-3099(20)30591-0. Epub 2020 Dec 7.

Authors

Paul E Verweij¹, Alexandre Alanio²

Affiliations

¹ Department of Medical Microbiology and Center of Expertise in Mycology Radboudumc/CWZ, Radboud University Medical Centre, Nijmegen, Netherlands. Electronic address: paul.verweij@radboudumc.nl.
² Mycology-Parasitology Department, Hôpital Saint-Louis, Molecular Mycology Unit, CNRS UMR2000, National Reference Centre for Invasive Mycoses and Antifungals, Institut Pasteur, Université de Paris, Paris, France.

No abstract available

Publication types

Letter

MeSH terms

COVID-19 / complications*
COVID-19 / diagnosis
COVID-19 Drug Treatment
Humans
Influenza, Human
Intensive Care Units
Mycoses / complications*
Mycoses / diagnosis
Mycoses / drug therapy
Mycoses / microbiology
Outcome Assessment, Health Care
Pulmonary Aspergillosis
Risk Factors
SARS-CoV-2